ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Leukemia · 2026 · PMC12789008 · PMID 41145670

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.13not close (p > 0.1)

Patients with elevated cfDNA (≥3.35 log 10 hGE/ml, as defined by a Cox regression model) showed a trend towards inferior PFS ( p = 0.13, HR = 3.1, 95% Cl=0.64–14.95) (Fig. 3E ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.